GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (HKSE:09969) » Definitions » Quality Rank

InnoCare Pharma (HKSE:09969) Quality Rank


View and export this data going back to 2020. Start your Free Trial

What is InnoCare Pharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

InnoCare Pharma Quality Rank Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Executives
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Cui Jisong
King Bridge Investments Limited 2101 Beneficial owner
Pang Kee Chan Hebert 2201 Interest of corporation controlled by you
Shi Yigong
Zhao Renbin
Sunny View Holdings Limited
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Hhlr Fund, L.p. 2101 Beneficial owner
Highbury Investment Pte Ltd 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Tmf (cayman) Ltd. 2301 Trustee
Sunland Biomed Ltd 2101 Beneficial owner